Federal grants to Illexcor Therapeutics, Inc.
Illexcor Therapeutics, Inc. in Richmond, Virginia received $5.0 million in federal grants from fiscal 2021 to 2025, across 3 awards. Its largest program was Cardiovascular Diseases Research, with $5.0 million. In fiscal 2025 it was awarded $1.3 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$5.0 million
- Awards3
- Awarded in FY 2025$1.3 million
- Largest award$2.4 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $298,412 |
| FY 2022 | 0 | -$8 |
| FY 2023 | 2 | $1.7 million |
| FY 2024 | 2 | $1.7 million |
| FY 2025 | 2 | $1.3 million |
Programs that fund Illexcor Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 3 | $5.0 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 3 | $5.0 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Rapid development of a lead aromatic aldehyde derivative with both oxygen dependent and novel, oxygen independent anti-sickling effects: building on a paradigm shift in sickle cell disease therapy - sickle cell disease (SCD) affects ~100,000 individuals in the us and millions more worldwide. The dis | Cardiovascular Diseases Research | August 23, 2023 | $2.4 million |
| Novel therapeutic approach for severe ards with a potent pharmacologic allosteric hemoglobin modifier - acute respiratory distress syndrome (ARDS) is a life-threatening condition featuring acute onset of non- cardiogenic respiratory failure and hypoxemia. Consequently, patients with ards have severe | Cardiovascular Diseases Research | June 26, 2023 | $2.4 million |
| Novel therapeutic approach for severe ards with a potent pharmacologic allosteric hemoglobin modifier - acute respiratory distress syndrome (ARDS) is a life-threatening condition featuring acute onset of non- cardiogenic respiratory failure and hypoxemia. Consequently, patients with ards have severe | Cardiovascular Diseases Research | December 28, 2020 | $298,400 |
Questions people ask
How much federal grant money does Illexcor Therapeutics, Inc. get?
$5.0 million in 3 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Illexcor Therapeutics, Inc. the most?
The Department of Health and Human Services, with $5.0 million in 3 awards.
What is Illexcor Therapeutics, Inc.'s largest federal grant?
$2.4 million under Cardiovascular Diseases Research, with its first action in the period on August 23, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Richmond
- VA Department of Medical Assistance Service
- Commonwealth of Virginia State Board of Education
- Virginia Department of Transportation
- Virginia Department of Social Services
- Housing & Community Development Virginia Department of
- VA Department of Transportation
- Emergency Mgmt Department of
- State Corporation Commission
Largest federal grant recipients in Virginia · Federal grants in Virginia